Shah S, Sacco P, Jackson L, Price M, Bensink M, Bernstein C. Beyond frequency alone - exploring what meaningful improvement means in the treatment of migraine: focus groups in patients and health care providers. Poster presented at the 2020 American Headache Society 62nd Virtual Annual Scientific Meeting; June 15, 2020. San Diego, CA.
Bhattacharyya S, Sacco P, Shirore R, Sonathi V, Thomas SK. A de novo economic model to assess the cost and quality of life consequences of an intervention for levodopa induced dyskinesia amongst patients with Parkinson's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A590-1.
Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the functional independence measure following spinal cord injury and long-term outcomes. Spinal Cord. 2012 Oct;50(10):728-33. doi: 10.1038/sc.2012.50
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Chen S, Wu N, Boulanger L, Sacco P. Economic burden of refractory epilepsy with partial onset seizures: an assessment of direct health care resource use and costs. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A143.
Wu N, Chen S, Boulanger L, Fraser K, Sacco P. Incidence, prevalence, and antiepileptic drug treatment patterns of patients with refractory partial onset seizures. Poster presented at the American Epilepsy Society; June 2011. Baltimore, MD.
Hollis KA, Calingaert B, Price M, Andrews E, Moy L, Kooijmans M, Cristiano L, Bozic C. Tysabri TOUCH prescriber program risk management program (RiskMAP) surveys. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010 Aug;26(8):1957-65. doi: 10.1185/03007995.2010.493788
Borah B, Sacco P, Zarotsky V. Predictors of adherence among alzheimer's disease patients receiving oral therapy: results of a retrospective database analysis. Presented at the American Academy of Neurology; April 2010. Toronto, Canada.
Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Shashidhar KH. Outcomes, impact and behavior associated with acute treatment of migraine. Poster presented at the 16th Migraine Trust International Symposium; November 2006. [abstract] Cephalalgia. 2006 Nov; 26(11):1358-403.
Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Kori SH. The migraine assessment of current therapy (Migraine-ACT): a useful tool for detecting differences in outcomes between migraine therapies. Poster presented at the Migraine Trust International Symposium; September 2006.
Sacco P, Luo R, Chang S, Sung D, Gause D. Potential benefits of rivastigmine in the nursing home population with alzheimer's disease. Poster presented at the Gerontological Society of America; December 2002. Boston, MA.